



Indicator Analysis 2026

Annual Report of the Certified Neuro-oncology Cancer Centres

Audit year 2025 / Indicator year 2024

Table of Content

Introduction 2

 General information 3

 Status of the certification system for Neuro-oncology Cancer Centres 2025 5

 Clinical sites taken into account 6

 Tumour documentation systems in the centre's clinical sites 7

 Basic data 8

Analysis of indicators 11

 Indicator No. 1a: Primary cases 11

 Indicator No. 1b: Patients with recurrence/progression 12

 Indicator No. 1c: Cerebral metastasis 13

 Indicator No. 2a: Interdisciplinary case discussions – primary cases elective pre-intervention..... 14

 Indicator No. 2b: Interdisciplinary case discussions – primary cases with histological/ molecular pathological findings..... 15

 Indicator No. 3: Psycho-oncological distress screening 16

 Indicator No. 4: Social service counselling 17

 Indicator No. 5: Patients enrolled in a study 18

 Indicator No. 6a: Surgical primary cases 21

 Indicator No. 6b: Biopsy 22

 Indicator No. 6c: Ratio biopsies/resections 23

 Indicator No. 7: Revision surgeries 24

 Indicator No. 8: Gliomas: Recommendation for combination therapy at the tumour board..... 25

 Indicator No. 9: Symptom assessment via MIDOS or IPOS 26

Imprint 27

General information

	Indicator definition	All clinical sites 2024			2023
		Median	Range	Patients Total	Patients Total
Numerator	Patients of the denominator who received psycho-oncological distress screening	128*	15 - 581	11,424	9,166
Denominator	Primary cases (= Indicator 1a) and patients with recurrence / progress (= Indicator 1b)	232,5*	106 - 820	18,933	17,401
Rate	Target value ≥ 65%	62.8%	10.3% - 96.6%	60.3%**	52.7%

Basic data indicator:

The definition of the **numerator**, the **denominator** and the **target value** are taken from the data sheet.

The column **Median** for numerator and denominator does not refer to a specific centre but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.

The column **Range** specifies the value range for the numerator, denominator and ratio of all centres.

The column **Patients Total** displays the total of all patients treated according to the indicator and the corresponding quota.





Diagram:


The x-axis indicates the number of centres. and the y-axis represents the values in percent or number (e.g. primary cases). The target value is depicted as a green horizontal line. The median, which is also depicted as a green horizontal line, divides the entire group into two equal halves.

General information



Cohort development:

The **cohort development** in the years **2020, 2021, 2022, 2023** and **2024** is presented in a boxplot diagram.



Boxplot:

A box plot consists of a **box with median, whiskers** and **outliers**. 50 percent of the centres are within the box. The median divides the entire available cohort into two halves with an equal number of centres. The whiskers and the box encompass a 90th percentile area/range. The extreme values are depicted here as dots.

Status of the certification system for Neuro-oncology Cancer Centres 2025

	31.12.2025	31.12.2024	31.12.2023	31.12.2022	31.12.2021	31.12.2020
Ongoing certification procedures	2	4	3	4	3	5
Certified Centres	70	66	60	56	53	46
Certified clinical sites	71	67	61	57	54	47
Neuro-oncology Centres with 1 clinical site	69	65	59	55	52	45
2 clinical sites	1	1	1	1	1	1
3 clinical sites	0	0	0	0	0	0
4 clinical sites	0	0	0	0	0	0

Clinical sites taken into account

	31.12.2025	31.12.2024	31.12.2023	31.12.2022	31.12.2021	31.12.2020
Sites considered in the annual report	70	64	60	56	51	44
correspond to	98.6%	95.5%	98.3%	98.2%	94.4%	93.6%
Primary cases total*	14,753	13,360	12,552	11,750	10,810	9,914
Primary cases per site (mean)*	210.8	208.8	209.2	209.8	211.9	225.3
Primary cases per site (median)*	185.0	177.0	178.0	183.5	178.0	184.5


*The figures are based on the clinical sites listed in the Annual Report.

This Annual Report looks at the Neuro-oncological centres certified in the certification system of the German Cancer Society. The basis for the diagrams in the Annual Report is the Data Sheet.

The Annual Report includes 70 of the 71 certified centre locations. Excluded is 1 clinical site that were certified for the first time in 2025 (data mapping of complete calendar year not mandatory for the initial certification). All 71 sites treated 14,855 primary neuro-oncological cases. A current overview of all certified sites is available at www.oncomap.de.

The indicators published here relate to the indicator year 2024 and provide the basis for the audits conducted in 2025.

Tumour documentation systems in the centre's clinical sites




Andere = Other


Legend:	
Other	Systems only used at one location

The details on the tumour documentation system was taken from the Data Sheet (Basic Data Sheet). It is not possible to use more than one system. In many cases, support is provided by the cancer registries or there may be a direct link to the cancer registry via a specific tumour documentation system.

Basic data – Stage distribution of primary cases of neuro-oncological tumours




Basic data - centre cases neuro-oncological tumours



Primary cases	Recurrences/Progressions	Centre cases
14,753 (77.9%)	4,180 (22.1%)	18,933 (100%)


Basic data - Surgical expertise (number of resections - number of biopsies)




Surgical expertise - Number of resections	Surgical expertise - Number of biopsies
19,388 (88.4%)	2,552 (11.6%)

Operative expertise: Resections or biopsies in primary cases, patients with recurrences/progressions and metastases in the calendar year are counted, regardless of primary case status.

1a. Primary cases




	Indicator definition	All clinical sites 2024			2023
		Median	Range	Patients total	Patients total
Number	Primary cases Definition in line with 1.2.1	185	102 - 610	14,753	13,360
	Target value ≥ 100				




	2020	2021	2022	2023	2024
Max	618	635	651	654	610
95 th percentile	403.5	391.5	352.2	354	384.9
75 th percentile	263.0	240.8	266.5	240.5	254
Median	178.0	183.5	178	177	185
25 th percentile	136.0	139.3	147.3	146.3	141.3
5 th percentile	117.5	105.3	113.9	120.1	112.4
Min	106	93	108	100	102

Clinical sites with evaluable data				Clinical sites meeting the target value			
2024		2023		2024		2023	
70	100%	64	100%	70	100%	64	100%
Comments: All centres meet the target value of at least 100 primary cases per year. The median of n = 185 primary cases/per representing a slight increase compared with the previous year. Total number of primary cases increased by 9% compared to the previous year, while number of centres increased by 9%. Primary cases involving malignant neoplasms account for around 34% of all primary cases. Benign neoplasms account for around 59% of all primary cases. Approximately 7% are primary cases of uncertain behaviour.							

1b. Patients with recurrence/progression




	Indicator definition	All clinical sites 2024			2023
		Median	Range	Patients total	Patients total
Number	Patients with recurrence/progression	50	3 - 229	4,180	4,041
	No target value				




	2020	2021	2022	2023	2024
Max	296	232	201	232	229
95 th percentile	175	166	155.7	148.6	138.1
75 th percentile	84	97.3	84.8	84.5	73
Median	47	55	49	44	50
25 th percentile	27	25.5	34.8	28.8	26
5 th percentile	9	11	13.9	8.3	7.9
Min	2	4	4	5	3

Clinical sites with evaluable data				Clinical sites meeting the target value			
2024		2023		2024		2023	
70	100%	64	100%	---	---	---	---
Comments: The median number of patients with recurrence or progression is 50 per centre. There is no target value for this metric. Compared with the previous year, there has been a 3.3% increase in the number of patients with recurrence or progression treated, alongside a 9% increase in the number of centres.							

1c. Cerebral metastases




	Indicator definition	All clinical sites 2024			2023
		Median	Range	Patients Total	Patients Total
Number	Patients with cerebral metastases treated in the NOC (tumourspecific diagnostics and/or treatment)	79,5	25 - 346	7,002	6,133
	No target value				




	2020	2021	2022	2023	2024
Max	336	310	391	384	346
95 th percentile	193.6	206.3	227.9	198.4	216.9
75 th percentile	104	106.5	130.5	138.3	130.3
Median	67	68.5	65.5	77.5	79.5
25 th percentile	41	45	46	46.5	51
5 th percentile	21.6	16	27.5	29.3	32
Min	1	2	5	1	25

Clinical sites with evaluable data		Clinical sites meeting the target value	
2024	2023	2024	2023
70	100%	64	100%
		---	---
		---	---
Comments: The number of patients with cerebral metastases treated in the Neuro-Oncology Centres (MNOCs) increased by 12% compared to the previous year (from 6,133 to 7,002).			

2a. Interdisciplinary case discussions - primary cases elective pre-intervention



	Indicator definition	All clinical sites 2024			2023
		Median	Range	Patients Total	Patients Total
Numerator	Elective primary cases, which were presented pre-intervention in the tumour board	142*	15 - 526	11,619	----
Denominator	Primary cases (= Indicator 1a)	185*	102 - 610	14,753	----
Rate	No target value	84.5%	12.5% - 100%	78.8%**	----




	2020	2021	2022	2023	2024
Max	----	----	----	----	100%
95 th percentile	----	----	----	----	97.3%
75 th percentile	----	----	----	----	93.3%
Median	----	----	----	----	84.5%
25 th percentile	----	----	----	----	70.8%
5 th percentile	----	----	----	----	42.2%
Min	----	----	----	----	12.5%

Clinical sites with evaluable data		Clinical sites meeting the target value	
2024	2023	2024	2023
70	100%	----	----


Comments:
The target value was modified in accordance with the decision taken at the 2024 meeting of the Certification Commission, meaning that no comparative figures are available for the results. No target had yet been set for the indicator year under review. Just under 79% of primary cases were presented at the centres as elective primary cases at the tumour board.
At least 95% of primary cases treated for the first time at the NOC must be presented to the tumour board, either electively prior to a decision on intervention or, in the case of emergencies, at the latest once the neuropathological/molecular diagnostic results are available.

*The median for numerator and denominator does not refer to an existing centre but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centres according to the numerator.

2b. Interdisciplinary case discussions - primary cases with histological/ molecular pathological findings



	Indicator definition	All clinical sites 2024			2023
		Median	Range	Patients Total	Patients Total
Numerator	Primary cases of the denominator, that were presented (again, if necessary) at the tumour board	145*	66 - 600	12,312	----
Denominator	Primary cases (= Indicator 1a)	153*	67 - 605	12,662	----
Rate	Target value ≥ 95%	98.2%	72.5% - 100%	97.2%**	----




	2020	2021	2022	2023	2024
Max	----	----	----	----	100%
95 th percentile	----	----	----	----	100%
75 th percentile	----	----	----	----	100%
Median	----	----	----	----	98.2%
25 th percentile	----	----	----	----	96.1%
5 th percentile	----	----	----	----	91.2%
Min	----	----	----	----	72.5%

Clinical sites with evaluable data				Clinical sites meeting the plausibility limits			
2024		2023		2024		2023	
70	100%	----	----	63	90%	----	----


Comments:
The target value was modified in accordance with the decision taken at the 2024 meeting of the Certification Commission, meaning that no comparative figures are available for the results. Approximately 97% of primary cases with histological/molecular pathological findings were presented at tumour conferences in the centres. 7 centres fell short of the target value. Reasons cited for falling short included, in some cases, a failure to present cases at the tumour board following pre-interventional presentation, documentation errors, or organisational issues with registration for the tumour board. Improvement measures have been initiated. A deviation has been noted.

*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centres according to the numerator.

3. Psycho-oncological distress screening



	Indicator definition	All clinical sites 2024			2023
		Median	Range	Patients Total	Patients Total
Numerator	Patients of the denominator who received psycho-oncological distress screening	128*	15 - 581	11,424	9,166
Denominator	Primary cases (= Indicator 1a) and patients with recurrence / progress (= Indicator 1b)	232,5*	106 - 820	18,933	17,401
Rate	Target value ≥ 65%	62.8%	10.3% - 96.6%	60.3%**	52.7%




	2020	2021	2022	2023	2024
Max	----	----	99.7%	97.1%	96.6%
95 th percentile	----	----	96.1%	81.3%	85.2%
75 th percentile	----	----	61.7%	65.5%	72.8%
Median	----	----	43.1%	54.6%	62.8%
25 th percentile	----	----	23.3%	29.3%	49.9%
5 th percentile	----	----	0.0%	10.7%	19.7%
Min	----	----	0.0%	0.0%	10.3%

Clinical sites with evaluable data		Clinical sites meeting the target value	
2024	2023	2024	2023
70	100%	64	100%
		33	47.1%
		18	28,1%


Comments:
Approximately 47% of the clinical sites meet the target value of ≥ 65%, which represents an increase of 19 percentage points compared with the previous year. 37 sites fall below this threshold. Reasons cited for non-compliance include challenges in process implementation, staff absences and turnover, difficulties in documentation, a deterioration in patients' general condition, or missing feedback. The centres responded with corrective and improvement measures. In 29 audits, recommendations were issued.

*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centres according to the numerator..

4. Social services counselling



	Indicator definition	All clinical sites 2024			2023
		Median	Range	Patients Total	Patients Total
Numerator	Patients of the denominator who received counselling by social services in an inpatient or outpatient setting	126.5*	9 - 716	10,379	8,977
Denominator	Primary cases (= Indicator 1a) and patients with recurrence/progress (= Indicator 1b)	232.5*	106 - 820	18,933	17,401
Rate	Mandatory justification*** <50%	53.7%	8.5% - 96.3%	54.8%**	51.6%




	2020	2021	2022	2023	2024
Max	91.7%	99.1%	96.0%	99.2%	96.3%
95 th percentile	78.4%	70.5%	73.4%	70.0%	85.7%
75 th percentile	61.2%	60.8%	61.3%	59.5%	62.5%
Median	52.3%	50.9%	50.9%	53.4%	53.7%
25 th percentile	43.5%	46.9%	43.4%	44.9%	48.7%
5 th percentile	27.7%	32.2%	22.6%	28.0%	26.9%
Min	17.3%	14.2%	11.7%	16.6%	8.5%

Clinical sites with evaluable data				Clinical sites meeting the plausibility limits			
2024		2023		2024		2023	
70	100%	64	100%	50	71.4%	44	68,8%


Comments:
Approximately 55% of primary cases and patients with recurrence/progression received counselling from the social services (previous year: 51.6%). The median counselling rate by the social service is roughly the same as the previous year. 20 centres were required to provide justification, 5 of which are located in German-speaking foreign countries, where social support is organised through different structures. The centres in Germany explained the shortfall, among other reasons, with counselling being offered but not requested by patients, staffing shortages, as well as a high proportion of benign primary cases without surgical indication, which did not result in inpatient admission or treatment.

*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centres according to the numerator.
*** For values outside the plausibility limit(s), the centres are required to provide a justification.

5. Patients enrolled in a study



	Indicator definition	All clinical sites 2024			2023
		Median	Range	Patients Total	Patients Total
Numerator	All patients (malignant and benign) who were included in a study with an ethical vote	33*	0 – 382	3,648	2,952
Denominator	Malignant primary cases	58.5*	18 – 149	4,914	4,573
Rate	Target value ≥ 5%	46.4%	0% - 454.8%	74.2%**	64.6%



		2020	2021	2022	2023	2024	Clinical sites with evaluable data		Clinical sites meeting the target value			
							2024	2023	2024	2023		
	Max	567.7%	915.3%	453.4%	477.0%	454.8%	70	100%	64	100%	64	91,4%
	95 th percentile	350.2%	245.4%	209.0%	201.9%	187.3%					61	95,3%
	75 th percentile	67.3%	66.2%	68.7%	65.9%	87.7%						
	Median	42.5%	42.2%	34.1%	28.0%	46.4%						
	25 th percentile	15.8%	15.6%	13.9%	12.0%	11.2%						
	5 th percentile	4.7%	5.4%	5.2%	5.7%	3.5%						
	Min	1.6%	3.6%	0.0%	0.0%	0.0%						
Comments: 91% of the centres meet the target value of ≥ 5%. The median study participation rate is 46%, representing a significant increase compared with the previous year. Furthermore, there is a wide range in the indicator value across centres (0 – 455%). 6 centres do not reach the target value of 5%. In 2 of these centres, compliance with the study quota was already demonstrated during the audit on the basis of current figures, due to ongoing study activities. During the audits, the centres presented their activities to establish new studies.												

*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.

** Percentage of total patients treated in centres according to the numerator.

Individual Annual Report – Benchmark


Individual Annual Report - Evaluation of site-specific key figures

What is the individual Annual Report?

In the individual annual report, the site-specific centre data is shown and compared to the other certified centres in the respective certification system of the German Cancer Society. In addition, the individual development of the centre is presented over the course of time. The content and design of an individual Annual Report are based on the general Annual Reports. An example of an individual Annual Report is available at www.onkozert.de under General Information / Annual Reports.

Who can receive the individual Annual Report?

The prerequisite for the preparation of the individual annual report is the publication of the general annual report (announcement on www.onkozert.de) as well as the depiction of the own centre in the general Annual Report (for example, centres with initial certification are not depicted in the audit year). In the case of multi-site centres, each site is shown in its own individual Annual Report. Only the general Annual Report is currently available for oncology centres.



	Indicator definition	Example centre				
		2020	2021	2022	2023	2024
Numerator	Patients referred by the denominator who received inpatient or outpatient counselling from social services	185	198	176	170	186
Denominator	Primary cases (= indicator 1a) + patients with newly occurring recurrence (local, regional LN metastases) and/or distant metastases (= indicator 1b)	305	338	333	335	305
Rate	Mandatory justification*** <50%	60.66%	58,58%	52.85%	50.75%	60.98%

Individual development of the example centre over time

**Excerpt from an Individual Annual Report
(indicator: Social Service Counselling)**

Individual Annual Report – Benchmark

How can I receive the individual Annual Report?

The individual Annual Report is made available for download as an electronic PowerPoint file on the [Data-WhiteBox](#) platform.

Access to an individual Annual Report differs depending on the certification system:


Colorectal, Prostate and Gynaecological Cancer Centres

- The individual Annual Report is made available for all Colorectal, Prostate and Gynaecological Cancer Centres by decision of the respective Certification Commission.
- The centres (centre management and centre coordination) are informed by email by OnkoZert about the availability of the respective individual Annual Report.
- The centres (centre management and centre coordination) are informed by email by OnkoZert about the availability of the respective individual Annual Report.


All other Organ Cancer Centres / Modules

- The centres (centre management and centre coordination) are informed by email by OnkoZert about the basic availability of the individual Annual Reports. From this point onwards, an individual Annual Report can optionally be ordered for a fee.
- The 'Individual Annual Report Order Form' is available at www.onkozert.de under General Information / Annual Reports. Orders can only be placed by persons who are registered with OnkoZert as contact persons (e.g. centre management, centre coordination, QMB, etc.)
- The costs for the respective individual Annual Reports are listed on the form.
- The preparation time is approx. 3 weeks after receipt of order.

6a. Surgical primary cases



	Indicator definition	All clinical sites 2024			2023
		Median	Range	Patients Total	Patients Total
Number	Surgical primary cases Definition in line with 5.2.3a	134.5	60 – 568	11,023	10,075
	Target value ≥ 60				




		2020	2021	2022	2023	2024	Clinical sites with evaluable data		Clinical sites meeting the target value			
							2024	2023	2024	2023		
	Max	613	630	618	594	568	70	100%	64	100%	70	100%
	95 th percentile	341.5	316.8	309.4	301.7	310.4						
	75 th percentile	192.5	183.3	195.8	174.8	184						
	Median	130	127.5	129.5	129.5	134.5						
	25 th percentile	108	100.8	101.8	94.5	94						
	5 th percentile	74.5	75	78.8	73.9	66.9						
	Min	65	59	63	65	60						


Comments:

All centres meet the target value of at least 60 surgical primary cases. The number of surgical primary cases increased from 10,075 to 11,023 (+8.6%) compared to the previous year, alongside an increase of 6 centres. Just under 75% of all primary cases are surgical primary cases.

6b. Biopsy




	Indicator definition	All clinical sites 2024			2023
		Median	Range	Patients Total	Patients Total
Number	Biopsies Definition in line with 5.2.3b	18	3 - 55	1,478	1,509
	No target value				




	2020	2021	2022	2023	2024
Max	85	70	77	96	55
95 th percentile	56.5	49.8	51.3	48.9	50.7
75 th percentile	26	28.3	26.3	29.5	26.5
Median	19	19.5	20.5	19.5	18
25 th percentile	14	14	14.8	12.8	11
5 th percentile	11.5	7	8.9	9	7
Min	11	5	5	4	3

Clinical sites with evaluable data		Clinical sites meeting the target value	
2024	2023	2024	2023
70	100%	64	100%
		---	---
		---	---
Comments: In the certified centres, 1,478 biopsies were performed on primary cases (OPS: 1-510; 1-511; 1-512; 1-514; 1-515)* compared to 1,509 in the previous year. The median is 18.0 biopsies, remaining largely stable over the years despite a gradual increase in the number of centres. The indicator has no target value. * 1-510: Intracranial biopsy by incision and craniotomy; 1-511: Stereotactic brain biopsy; 1-512: Incisional intraspinal biopsy; 1-514: Biopsy of hypophysis and pineal gland by incision; 1-515: Stereotactic biopsy of hypophysis and pineal gland; available at https://gesund.bund.de/en/ .			

6c. Ratio biopsies/resections




	Indicator definition	All clinical sites 2024			2023
		Median	Range	Patients Total	Patients Total
Numerator	Biopsies primary cases (= Indicator 6b)	18*	3 - 55	1,478	1,509
Denominator	Surgical primary cases (= Indicator 6a)	134.5*	60 – 568	11,023	10,075
Rate	Mandatory justification*** <10% and >25%	12.9%	4.3% - 27.2%	13.4%**	15%




		2020	2021	2022	2023	2024	Clinical sites with evaluable data		Clinical sites meeting the plausibility limits			
							2024	2023	2024	2023		
	Max	54.7%	32.9%	30.7%	33.8%	27.2%	70	100%	64	100%	51	72.9%
	95 th percentile	35.1%	25.0%	25.6%	25.0%	23.8%					50	78,1%
	75 th percentile	20.0%	19.2%	19.1%	20.7%	16.7%						
	Median	13.3%	13.5%	14.7%	13.4%	12.9%						
	25 th percentile	10.6%	10.0%	10.4%	10.7%	10.8%						
	5 th percentile	7.4%	5.3%	7.1%	7.5%	5.2%						
	Min	4.0%	4.4%	3.7%	3.3%	4.3%						
Comments: For the indicator “biopsy-to-resection ratio,” both an upper and a lower threshold are defined for mandatory justification. 73% of the centres fall within the plausibility limits. 16 centres have a ratio of < 1:10 and justify this with their patient cohort (e.g. high proportion of benign tumours, high proportion of multifocal lesions) or with the centre’s high level of expertise in stereotaxy or a high proportion of awake craniotomies. 3 centres have a ratio of > 25% and attribute this to tumour location, multifocal lesions, and the site’s specialisation in stereotaxy.												

* The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centres according to the numerator.
*** For values outside the plausibility limit(s), the centres are required to provide a justification.

7. Revision surgeries



	Indicator definition	All clinical sites 2024			2023
		Median	Range	Patients Total	Patients Total
Numerator	Primary cases of the denominator with revision surgery due to post-operative complications within 30d after surgery	7*	1 – 22	582	567
Denominator	Surgical primary cases (= Indicator 6a)	134.5*	60 – 568	11,023	10,075
Rate	Target value ≤ 10%	5.3%	1% - 10.7%	5.3%**	5.6%




	2020	2021	2022	2023	2024
Max	12.4%	12.9%	12.4%	12.7%	10.7%
95 th percentile	10.7%	9.8%	9.3%	10.0%	9.0%
75 th percentile	8.6%	7.6%	6.8%	7.5%	7.1%
Median	6.0%	5.2%	5.1%	5.6%	5.3%
25 th percentile	4.3%	3.1%	4.1%	3.5%	3.7%
5 th percentile	2.1%	2.2%	2.0%	1.5%	2.2%
Min	0.0%	1.1%	1.5%	0.0%	1.0%


Clinical sites with evaluable data		Clinical sites meeting the target value	
2024	2023	2024	2023
70	100%	64	100%
69	98.6%	61	95.3%
Comments: With the exception of one centre, all centres have a revision surgery rate below the target value of ≤ 10%. In approximately 5.3% of operative primary cases, a revision surgery was necessary. The centre, which narrowly exceeded the target value by 10.7%, analysed the cases, organised further training for staff and presented the findings of the analysis in the audit. No non-conformity was identified.			

*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centres according to the numerator.

8. Gliomas: Recommendation for combination therapy at the tumour board



	Indicator definition	All clinical sites 2024			2023
		Median	Range	Patients Total	Patients Total
Numerator	Primary cases in the denominator for which a combination of radiotherapy and chemotherapy following surgery was recommended as the primary treatment at the tumour board	29.5*	0 - 118	2,105	----
Denominator	New cases of gliomas classified as WHO grade ≥ 3 that were discussed at the tumour board	45.5*	9 - 160	2,943	----
Rate	No target value	80.3%	0% - 100%	71.5%**	----




		2020	2021	2022	2023	2024	Clinical sites with evaluable data		Clinical sites meeting the target value			
							2024	2023	2024		2023	
●	Max	----	----	----	----	100.0%	58	82,9%	----	----	----	----
	95 th percentile	----	----	----	----	95.9%						
	75 th percentile	----	----	----	----	85.9%						
	Median	----	----	----	----	80.3%						
	25 th percentile	----	----	----	----	66.9%						
	5 th percentile	----	----	----	----	0.0%						
●	Min	----	----	----	----	0.0%						

Comments:

This indicator was collected for the first time and is still optional. There is no target value for this indicator. Actionable data is available for 58 of the 70 clinical sites. For approximately 72% of primary cases involving WHO grade ≥ 3 gliomas discussed at the tumour board, a combination of radiotherapy and chemotherapy following surgery was recommended as the primary treatment.


*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centres according to the numerator.

9. Symptom assessment via MIDOS or IPOS



	Indicator definition	All clinical sites 2024			2023
		Median	Range	Patients Total	Patients Total
Numerator	Patients of the denominator with symptom assessment via MIDOS or IPOS	33,5*	0 - 168	3,110	2,480
Denominator	Primary cases and patients with recurrence / progression with ICD-O topography C71 and ICD-O morphology /3	84*	8 - 278	6,844	6,522
Rate	Mandatory justification*** < 60%	50.6%	0% - 98.7%	45.4%**	38%

IPOS = Integrated Palliative care Outcome Scale



	2020	2021	2022	2023	2024
Max	----	----	100%	100%	98.7%
95 th percentile	----	----	78.5%	84.9%	89.9%
75 th percentile	----	----	40.8%	61.3%	68.0%
Median	----	----	26.2%	34.1%	50.6%
25 th percentile	----	----	13.4%	17.7%	24.9%
5 th percentile	----	----	0.0%	0.0%	0.9%
Min	----	----	0.0%	0.0%	0.0%

Clinical sites with evaluable data				Clinical sites meeting the plausibility limits			
2024		2023		2024		2023	
70	100%	64	100%	28	40%	19	29.7%

Comments:

In approximately 45% of the patients considered, symptom assessment was carried out using MIDOS or IPOS (previous year: 38%). About 40% of the centres achieved rates above 60%, which represents an increase of around 10 percentage points compared with the previous year. Centres, who needed to provide justification, primarily cited challenges in data collection, and took steps to address these by organising training sessions or seeking to digitise the screening process. Improvement measures were developed within the centres.

*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.

** Percentage of total patients treated in centres according to the numerator.

*** For values outside the plausibility limit(s), the centres are required to provide a justification.

WISSEN AUS ERSTER HAND (FIRST-HAND KNOWLEDGE)



Find out more on www.krebsgesellschaft.de

Authors

German Cancer Society (DKG)
Certification Committee for Neuro-oncology Cancer Centres
Uwe Schlegel, Spokesman Certification Committee
Walter Stummer, Spokesman Certification Committee
Birgit Klages, German Cancer Society (DKG)
Martin Utzig, German Cancer Society (DKG)
Ellen Griesshammer, German Cancer Society (DKG)
Nikoloz Gambashidze, German Cancer Society (DKG)
Viktoria Sonnentag, OnkoZert
Christin Bauer, OnkoZert
Florina Dudu, OnkoZert

Imprint

Publisher and responsible for content:
Deutsche Krebsgesellschaft (DKG)
Kuno-Fischer-Straße 8
14057 Berlin
Tel.: +49 (030) 322 93 29 0
Vereinsregister Amtsgericht Charlottenburg.
Vereinsregister-Nr.: VR 27661 B
V.i.S.d.P.: Dr. Johannes Bruns

in cooperation with:
OnkoZert. Neu-Ulm
www.onkozert.de

Version e-A1-de; 10.03.2026

ISBN: 978-3-912231-27-4

